Cardiosense, Inc.

Based in the US, Cardiosense, Inc. specializes in developing advanced digital biomarker platforms utilizing multi-sensor wearable devices to detect early signs of cardiac disease and offer personalized therapy solutions. Cardiosense, Inc. is focused on cardiac health management, providing cutting-edge solutions for early disease detection.

The company is headquartered in Chicago, US. Founded by Amit Gupta and Andrew Carek, Cardiosense has raised a total of USD 9. 08 mn in Series A funding on November 29, 2022, co-led by Broadview Ventures and Hatteras Venture Partners, among other investors. The current company valuation stands at USD 28.

33 mn. Cardiosense offers an advanced digital biomarker platform that integrates innovative, multi-sensor wearable devices and proprietary algorithms designed to identify early signs of cardiac disease and facilitate personalized therapy. Their flagship product, the CardioTag Sensor, is a medical-grade wearable device capable of wireless monitoring of patients, providing a seamless transition from in-hospital to home care. This device works in conjunction with the Wavesense Platform, a device-agnostic software solution that aggregates, transmits, and analyzes physiological sensor data, effectively mining raw biosignals for improved visibility into cardiac function.

Through the application of deep learning algorithms to raw physiological waveforms, Cardiosense develops digital biomarkers targeted at early disease detection, which ultimately aims to enhance patient care. The company primarily serves healthcare providers and institutions across North America and Europe, focusing on clients who are involved in cardiac care management. Cardiosense’s revenue structure is based on a combination of direct sales, subscription models, and partnerships with healthcare providers and institutions. Transactions typically occur through B2B relationships where hospitals and clinics acquire their CardioTag Sensors along with access to the Wavesense Platform for an integrated patient monitoring solution.

These clients may engage in annual subscription agreements to access continuous software updates and analytics features, providing ongoing value beyond initial device sales. The company’s products cater to a specialized segment within the healthcare market, focusing on cardiac disease management, emphasizing the importance of their offerings in enhancing patient outcomes. Specific pricing plans for these products are structured to reflect the value of improved patient monitoring and early disease detection capabilities, aligning with the needs of their client base in the healthcare sector. In November 2022, Cardiosense, Inc.

raised USD 9. 08 mn in Series A funding to advance new product development, hire additional employees, and conduct a heart failure study. The company plans to expand its offerings, including the development of upcoming products aimed at enhancing cardiac health management. They are strategically targeting growth in North America and Europe, with plans to increase their market presence significantly by the end of 2023.